2009-11-11 10:12:02 -

Five Prime Therapeutics, Inc., a clinical stage biologics company focused on discovery and development of innovative protein and antibody therapeutics, announced today that Julia P. Gregory, FivePrime’s president and chief executive officer, will present at the Lazard Capital Markets 6 th Annual Healthcare Conference at The St.

Regis Hotel, in New York, New York on Wednesday, November 18, 2009 at 2:45 p.m. Eastern Time. Ms. Gregory will discuss FivePrime’s advancing pipeline and business strategy.

About Five Prime Therapeutics, Inc.


Five Prime Therapeutics, Inc. is a clinical stage, privately-held company discovering and developing innovative protein and antibody therapeutics. Using its world-class biologics discovery platform, FivePrime is building a strong product pipeline in oncology, immunology and metabolic diseases. It has engineered a unique suite

of technologies to comprehensively mine the entire extracellular human proteome- the complete collection of secreted proteins and receptors- to discover its therapeutic protein drugs and antibody targets. FivePrime is currently in Phase I with FP-1039 for solid tumors. Pharmaceutical partners include Johnson & Johnson’s Centocor division and Pfizer, Inc. For more information, please visit www.fiveprime.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .



Five Prime Therapeutics, Inc.Jennifer Pratt Mead, 415-365-5663Director,
Corporate Communications Jennifer.pratt@fiveprime.com : mailto:Jennifer.pratt@fiveprime.com